Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450435 | 0.80 | TP53 (0.36) | — | |
| SCHEMBL190837 | 0.71 | HSD11B1 (0.47) | HSD11B1KDM4DPDE10AKAT6AKAT8 | |
| SCHEMBL3448280 | 0.70 | KMT2A (0.46) | — | |
| SCHEMBL15112036 | 0.70 | L3MBTL1 (0.46) | HSD11B1PDE10ABUB1AAK1 | |
| SCHEMBL26342397 | 0.70 | L3MBTL1 (0.46) | HSD11B1PDE10ABUB1AAK1 | |
| SCHEMBL15115726 | 0.70 | L3MBTL1 (0.46) | HSD11B1PDE10ABUB1AAK1 | |
| SCHEMBL3450969 | 0.70 | FAAH (0.34) | — | |
| SCHEMBL3449704 | 0.68 | CALCRL (0.37) | — | |
| SCHEMBL132146 | 0.67 | HSD11B1 (0.42) | HSD11B1KDM4DPDE10AKAT6AKAT8 | |
| SCHEMBL4162004 | 0.67 | HSD11B1 (0.43) | HSD11B1KDM4DPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | HSD11B1 4053/4885KDM4D 1153/4885PDE10A 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.